Stock analysts at Robert W. Baird initiated coverage on shares of Genocea Biosciences (NASDAQ:GNCA) in a research note issued on Monday. The brokerage set an “outperform” rating and a $3.00 price target on the biotechnology company’s stock. Robert W. Baird’s price objective would indicate a potential upside of 192.68% from the stock’s current price.

GNCA has been the topic of several other reports. Zacks Investment Research lowered Genocea Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, January 3rd. Needham & Company LLC raised Genocea Biosciences from a “hold” rating to a “buy” rating and set a $3.00 price objective on the stock in a report on Tuesday, February 6th. Finally, Piper Jaffray Companies reissued an “overweight” rating and issued a $5.00 price objective on shares of Genocea Biosciences in a report on Thursday, November 2nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $4.21.

Shares of Genocea Biosciences (GNCA) opened at $1.03 on Monday. The company has a debt-to-equity ratio of 2.51, a current ratio of 1.55 and a quick ratio of 1.55. Genocea Biosciences has a 1-year low of $0.79 and a 1-year high of $7.29. The company has a market capitalization of $84.12, a P/E ratio of -0.47 and a beta of 1.55.

Several large investors have recently modified their holdings of GNCA. GSA Capital Partners LLP acquired a new stake in shares of Genocea Biosciences in the second quarter worth approximately $100,000. Ameriprise Financial Inc. boosted its stake in shares of Genocea Biosciences by 11.5% in the second quarter. Ameriprise Financial Inc. now owns 22,233 shares of the biotechnology company’s stock worth $119,000 after acquiring an additional 2,300 shares during the last quarter. Rhumbline Advisers acquired a new stake in shares of Genocea Biosciences in the second quarter worth approximately $157,000. New York State Common Retirement Fund acquired a new stake in shares of Genocea Biosciences in the second quarter worth approximately $159,000. Finally, OxFORD Asset Management LLP acquired a new stake in shares of Genocea Biosciences in the second quarter worth approximately $204,000. 12.03% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://theolympiareport.com/2018/02/14/genocea-biosciences-gnca-receives-new-coverage-from-analysts-at-robert-w-baird.html.

Genocea Biosciences Company Profile

Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.

Analyst Recommendations for Genocea Biosciences (NASDAQ:GNCA)

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.